Blends
Neuroxelin
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as Selank + Semax + others (nootropic blend)
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
Neuroxelin is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
Neuroxelin is a vendor-created name for a pre-mixed peptide blend sold by research-chemical suppliers, not a distinct molecule with an international nonproprietary name or a chemical registry entry. Product listings typically describe a fixed-ratio combination of N-acetyl Semax and N-acetyl Selank, the two Russian heptapeptides, sometimes with additional short peptides such as Pinealon or PE-22-28 depending on the seller. It is marketed as a nootropic blend intended to combine the cognition-oriented profile attributed to Semax with the anxiolytic profile attributed to Selank. Because the composition is defined by each vendor, two products carrying the same name may differ in constituents, ratios, and total content.
There is no peer-reviewed human or animal literature on Neuroxelin as a blend, and no clinical trial, pharmacokinetic study, or safety assessment of the combined product has been published. Whatever evidence is cited by sellers is borrowed from the individual components. Semax has Russian clinical trials and rodent studies describing BDNF induction and neuroprotection, summarised in a 1997 review by its developers. Selank has one small Russian comparator trial in generalised anxiety disorder and rodent anxiolytic studies. Neither body of work has been independently replicated outside Russia and Eastern Europe, and neither examined the N-acetyl variants or their co-administration with other peptides, so the blend's effects are inferred rather than demonstrated.
No regulator has evaluated or approved Neuroxelin. Its constituent peptides are registered medicines only in Russia, and the FDA compounding bulk drug substances review described both Semax and Selank acetate as presenting immunogenicity risk from aggregation and peptide-related impurities. In the United States, European Union, United Kingdom, and Australia the blend is an unlicensed product that cannot lawfully be marketed for human use, and it is sold under research-chemical labelling that disclaims human consumption. It is offered as a lyophilised powder for reconstitution and injection and as a nasal spray. Independent verification of identity, purity, ratio, or sterility is not available for any listing.
As a blend of several peptides in one vial, Neuroxelin presents storage and record-keeping questions that single compounds do not. Each constituent has its own stability profile, and no manufacturer data exist for the mixture, so the supplier statement is the only guidance on shelf life before and after reconstitution. Peptide solutions are sensitive to heat, light, and freeze-thaw cycling. For anyone tracking such a product, a dose log that records the vendor, lot number, the stated constituents and their labelled amounts, the diluent and reconstitution date, the route, and the storage temperature, alongside an inventory record of vials on hand, is the only traceability available in the absence of a regulated label.
- Category
- Blends
- Routes represented
- Subcutaneous (SubQ)
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
No verified PubMed or DOI link is available for this entry.
Safety evidence
Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.
A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.
Safety evidence sourceCommon questions
What is Neuroxelin?
Neuroxelin is a brand-style name used by research-chemical vendors for a fixed-ratio blend of nootropic peptides, most often N-acetyl Semax and N-acetyl Selank with one or more additional short peptides. It is not a recognised drug substance and has no pharmacopoeial or regulatory definition, so the exact contents depend on the seller. It is marketed for focus, memory, and stress resilience without published evidence for the combination.
Is there any research on Neuroxelin?
No. There are no peer-reviewed studies, clinical trials, or pharmacokinetic reports on the Neuroxelin blend. Claims rest on the separate literature for Semax and Selank, which consists mainly of Russian trials and rodent studies that have not been independently replicated. Those studies used the original peptides as nasal drops, not N-acetyl derivatives, and did not test co-administration with other peptides.
Is Neuroxelin legal or FDA-approved?
Neuroxelin is not approved by the FDA, EMA, MHRA, or TGA, and no regulator has reviewed the blend. Its constituents Semax and Selank were flagged by the FDA bulk substances review for immunogenicity and impurity risk. It is not a scheduled controlled substance in most jurisdictions, but it cannot lawfully be sold as a medicine, and vendors label it for research use only.
What is the difference between Neuroxelin and taking Semax and Selank separately?
The difference is control over composition. Separate products allow the amount and timing of each peptide to be recorded individually, whereas a blend fixes the ratio chosen by the vendor and adds constituents that may vary between sellers. Because the individual peptides have distinct proposed mechanisms, GABA modulation for Selank and BDNF induction for Semax, a blend also makes attributing any observed effect to a specific component impossible.
Further reading
- Ashmarin et al., A nootropic adrenocorticotropin analog 4-10 Semax: 15 years of design and study, 1997
- Dolotov et al., Semax regulates BDNF and trkB expression in the rat hippocampus, 2006
- Zozulia et al., Efficacy and mechanisms of the peptide anxiolytic Selank in generalized anxiety disorder and neurasthenia, 2008
- Vyunova et al., Peptide-based anxiolytics: molecular aspects of heptapeptide Selank biological activity, 2018
- FDA, Certain bulk drug substances for use in compounding may present significant safety risks
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.